Zhongnan Medical Journal Press

Home Results

A total of 8 result was found. Results that relate to Markov model

Cost-utility analysis of sacubitril/valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction

Published on Chinese Journal of Pharmacoepidemiology 2023,32(8):878-885.
1539 times 525 times

Dan-Dan LU Sheng-Xiang WANG Shan LU Dan PAN Li-Yuan SHI Fei-Chuang Jing2

Heart failure with reduced ejection fraction Sacubitril/valsartan Dapagliflozin Empagliflozin Markov model Cost-utility analysis
Details
Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2023,32(11):1259-1266.
1457 times 524 times

Xi ZHAO Xi YAN Ning LI Chun-Xia HOU

Abemaciclib Fulvestrant Hormone receptor-positive breast cancer Markov model Cost-effectiveness analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1371-1379.
1128 times 455 times

La-Ji DANZENG Yong-Gong YANG Si-Liang WANG Meng-Ying LIU

Azacitidine Decitabine Myelodysplastic syndrome Markov model Cost-utility analysis Pharmacoeconomics
Details
Pharmacoeconomic evaluation of different doses of rivaroxaban for the prevention of thrombosis in patients with nonvalvular atrial fibrillation

Published on Frontiers in Pharmaceutical Sciences 2023,36(11):233-240.
1113 times 522 times

Wei LUO Xue-Ying PENG Dong YANG Xin-Mei WU

Nonvalvular atrial fibrillation Rivaroxaban Dose selection Markov model Cost-utility analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):269-276.
1028 times 517 times

YANG Lei WANG Fengling HUANG Ling LI Yan ZHENG Hanrui ZHENG Lingli CHEN Li

Enzalutamide Metastatic prostate cancer Markov model Cost-effectiveness analysis
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus

Published on Chinese Journal of Pharmacoepidemiology 2024,33(4):388-401.
1298 times 965 times

YU Tian LIU Shaohua WEI Anhua GUO Jieru ZHANG Chengliang LIU Dong LIU Zhelong

Glucagon-like peptide-1 receptor agonist Metformin Type 2 diabetes mellitus Cost-utility Markov model Pharmacoeconomics
Details
Pharmacoeconomic evaluation of aflibercept versus conbercept for the treatment of wet age-related macular degeneration

Published on Frontiers in Pharmaceutical Sciences 2024,27(4):655-662.
1128 times 403 times

LIU Dan ZHANG Bochao ZHANG Jing WANG Juan YUAN Yi GUI Lin CHEN Li

Wet age-related macular degeneration Aflibercept Conbercept Markov model Pharmacoeconomic analysis
Details
Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/ vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(7):721-730.
1198 times 307 times

DING Xueru LIU Huimin HE Xiaodong LI Hua LI Zhihao

Fluticasone furoate/umeclidinium/vilanterol Chronic obstructive pulmonary disease Markov model Cost-utility analysis Pharmacoeconomic
Details